Loading clinical trials...
Loading clinical trials...
An Exploratory, Randomized, Double-Blind, Placebo-Controlled and Open-label Extension Study of the Safety, Tolerability, and Efficacy of Arbaclofen in Subjects With 16p11.2 Deletion
Conditions
Interventions
Arbaclofen
Placebo oral tablet
Locations
4
United States
Boston Children's Hospital
Boston, Massachusetts, United States
New York State Psychiatric Institute (NYSPI)
New York, New York, United States
Texas Children's Hospital
Houston, Texas, United States
University of Washington
Seattle, Washington, United States
Start Date
September 1, 2022
Primary Completion Date
December 22, 2024
Completion Date
March 23, 2025
Last Updated
May 30, 2024
Lead Sponsor
Clinical Research Associates, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions